Skin & Cosmetic Preliminary evidence

RIGIN

Palmitoyl tripeptide-1

Also known as: Rigin, Palmitoyl oligopeptide, Pal-GHK

In plain language

RIGIN is a synthetic peptide used in anti-aging skincare and marketed to support a more even, youthful look in mature skin. Most supporting data is in-vitro or manufacturer-sponsored, so independent human evidence is sparse.

What it is explored for

RIGIN is built on the well-loved GHK sequence and is marketed for a more even, youthful look in mature skin. Most support is in-vitro or manufacturer-based and independent human evidence is sparse, so it is best seen as a gentle ingredient to explore within a thoughtful skincare routine rather than a proven anti-aging fix.

  • A more even, youthful-looking complexion
  • Support for mature and aging-looking skin
  • Skin firmness and a smoother surface look
  • Support for the skin's natural matrix activity
  • Daily anti-aging serums and creams

These are areas of active interest and reported use, not proven outcomes. This peptide carries a preliminary evidence rating, see the evidence summary below for how strong the science actually is.

How it works

RIGIN is a palmitoylated tripeptide built on the GHK sequence and marketed for benefits associated with skin aging. The rationale centers on signaling and matrix support.

  • Matrikine signaling. It is marketed as a signal peptide associated with modulating cytokines such as interleukin-6 and supporting skin matrix activity.
  • Lipid conjugation. The palmitoyl group is added to improve fat solubility and help the peptide penetrate the skin barrier.
  • Surface conditioning. As with many serums, some perceived benefit may reflect hydration and film-forming effects of the formulation.

The signaling mechanism is supported mainly by in-vitro work and manufacturer rationale rather than robust human data.

Evidence summary

Published independent evidence for RIGIN is sparse, with most support from in-vitro studies and manufacturer materials. Any benefit for the appearance of aging skin should be regarded as preliminary.

Reported safety & side effects

RIGIN is generally considered well tolerated in leave-on cosmetics at typical use levels, with a low reported rate of irritation. Independent safety data are sparse.

Typical reactionsGenerally well tolerated; irritation uncommon
Use contextTopical leave-on cosmetics (creams
Human safety dataSparse independent data; not an approved drug

Frequently asked

What is RIGIN marketed to do?

It is marketed to support a more even, youthful look in mature skin, based on proposed effects on skin signaling and the matrix.

Is there strong human evidence?

No. Support comes mostly from in-vitro work and manufacturer materials, so the evidence in living human skin is preliminary.